Treating Inflammatory Bowel Disease With Diet: A Taste Test

João Sabino; James D. Lewis; Jean Fréderic Colombel

doi:10.1053/j.gastro.2019.06.027

Treating Inflammatory Bowel Disease With Diet: A Taste Test

João Sabino, James D. Lewis, Jean Fréderic Colombel

Research output: Contribution to journal › Editorial

21 Scopus citations

Original language	English
Pages (from-to)	295-297
Number of pages	3
Journal	Gastroenterology
Volume	157
Issue number	2
DOIs	https://doi.org/10.1053/j.gastro.2019.06.027
State	Published - Aug 2019

Access to Document

10.1053/j.gastro.2019.06.027

Cite this

@article{e1e58533f6214ac1b4c7b8799cad72ab,

title = "Treating Inflammatory Bowel Disease With Diet: A Taste Test",

author = "Jo{\~a}o Sabino and Lewis, {James D.} and Colombel, {Jean Fr{\'e}deric}",

note = "Funding Information: Conflicts of interest The disclose the following: Jo{\~a}o Sabino has received speaker fees from Abbvie and Nestle Health Sciences. Jean-Fr{\'e}deric Colombel reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Eli Lilly, Medimmune, Merck, Novartis, Pfizer, Protagonist Therapeutics, Sandoz, Second Genome, Seres Therapeutics, Shire, Takeda, Theradiag and Theravance Biopharma; and hold stock options in Intestinal Biotech Development and Genfit. James Lewis has received speaker fees from Nestle Health Science; has received research funding from Takeda, Nestle Health Science, and Janssen Pharmaceuticals; and consulting honorarium from Takeda, Merck, Celgene, AbbVie, Janssen Pharmaceuticals, Eli Lilly and Company, Samsung Bioepis, Pfizer, Gilead, UCB, and Bridge Biotherapeutics. Conflicts of interest The disclose the following: Jo{\~a}o Sabino has received speaker fees from Abbvie and Nestle Health Sciences. Jean-Fr{\'e}deric Colombel reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Eli Lilly, Medimmune, Merck, Novartis, Pfizer, Protagonist Therapeutics, Sandoz, Second Genome, Seres Therapeutics, Shire, Takeda, Theradiag and Theravance Biopharma; and hold stock options in Intestinal Biotech Development and Genfit. James Lewis has received speaker fees from Nestle Health Science; has received research funding from Takeda, Nestle Health Science, and Janssen Pharmaceuticals; and consulting honorarium from Takeda, Merck, Celgene, AbbVie, Janssen Pharmaceuticals, Eli Lilly and Company, Samsung Bioepis, Pfizer, Gilead, UCB, and Bridge Biotherapeutics.",

year = "2019",

month = aug,

doi = "10.1053/j.gastro.2019.06.027",

language = "English",

volume = "157",

pages = "295--297",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Treating Inflammatory Bowel Disease With Diet

T2 - A Taste Test

AU - Sabino, João

AU - Lewis, James D.

AU - Colombel, Jean Fréderic

N1 - Funding Information: Conflicts of interest The disclose the following: João Sabino has received speaker fees from Abbvie and Nestle Health Sciences. Jean-Fréderic Colombel reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Eli Lilly, Medimmune, Merck, Novartis, Pfizer, Protagonist Therapeutics, Sandoz, Second Genome, Seres Therapeutics, Shire, Takeda, Theradiag and Theravance Biopharma; and hold stock options in Intestinal Biotech Development and Genfit. James Lewis has received speaker fees from Nestle Health Science; has received research funding from Takeda, Nestle Health Science, and Janssen Pharmaceuticals; and consulting honorarium from Takeda, Merck, Celgene, AbbVie, Janssen Pharmaceuticals, Eli Lilly and Company, Samsung Bioepis, Pfizer, Gilead, UCB, and Bridge Biotherapeutics. Conflicts of interest The disclose the following: João Sabino has received speaker fees from Abbvie and Nestle Health Sciences. Jean-Fréderic Colombel reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Eli Lilly, Medimmune, Merck, Novartis, Pfizer, Protagonist Therapeutics, Sandoz, Second Genome, Seres Therapeutics, Shire, Takeda, Theradiag and Theravance Biopharma; and hold stock options in Intestinal Biotech Development and Genfit. James Lewis has received speaker fees from Nestle Health Science; has received research funding from Takeda, Nestle Health Science, and Janssen Pharmaceuticals; and consulting honorarium from Takeda, Merck, Celgene, AbbVie, Janssen Pharmaceuticals, Eli Lilly and Company, Samsung Bioepis, Pfizer, Gilead, UCB, and Bridge Biotherapeutics.

PY - 2019/8

Y1 - 2019/8

UR - http://www.scopus.com/inward/record.url?scp=85069568621&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2019.06.027

DO - 10.1053/j.gastro.2019.06.027

M3 - Editorial

C2 - 31254503

AN - SCOPUS:85069568621

SN - 0016-5085

VL - 157

SP - 295

EP - 297

JO - Gastroenterology

JF - Gastroenterology

IS - 2

ER -